2月3日 - ** 生物制药公司Neuren Pharmaceuticals NEU.AX股价暴跌22.1%至12.660澳元，创下2018年8月初以来最大盘中跌幅。
** 该股是 ASX 200 指数 .AXJO的最大拖累，该指数上涨了 1.3%。
** NEU称， (link) 许可证持有者Acadia Pharmaceuticals ACAD.O 报告称，欧洲药品管理局的一个委员会对其特罗菲肽药物的上市许可申请投出了负面趋势票
** 补充说，根据该委员会2月份的投票结果，ACAD计划在意见正式通过后申请重新审查
** 特罗非肽是一种用于治疗雷特综合症的药物
** 股票连续第八个交易日下跌
** 换手率超过 459,500 股，是 30 天平均换手率的 1.5 倍
** 今年以来股价下跌 20.9%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.